Literature DB >> 21176961

Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia.

George Deeb1, Mary M Vaughan, Ian McInnis, Laurie Ann Ford, Sheila N J Sait, Petr Starostik, Meir Wetzler, Terry Mashtare, Eunice S Wang.   

Abstract

We examined the predictive impact of HIF-1α protein expression on clinical outcome of 84 normal karyotype acute myeloid leukemia (NK-AML) patients (median age 66.5 years) at our institute. Thirty percent of NK-AML cells expressed cytoplasmic HIF-1α. In univariate analysis, low HIF-1α (≤ 5%, n = 66) was associated with improved event-free survival (p = 0.0453, HR = 0.22). Multivariate analysis incorporating age, complete remission, FLT3-ITD mutation, and marrow blast percentage demonstrated that HIF-1α was independently associated with poorer overall and event-free survival. HIF-1α expression correlated with VEGF-C but not VEGF-A, marrow angiogenesis, FLT3 ITD or NPM1 mutations. These results support HIF-1α as an outcome marker for NK-AML.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21176961     DOI: 10.1016/j.leukres.2010.10.020

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  24 in total

1.  Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Authors:  Talha Badar; Damian R Handisides; Juliana M Benito; Mary Ann Richie; Gautam Borthakur; Elias Jabbour; Karine Harutyunyan; Sergej Konoplev; Stefan Faderl; Stew Kroll; Michael Andreeff; Tillman Pearce; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Marina Konopleva
Journal:  Am J Hematol       Date:  2016-06-25       Impact factor: 10.047

2.  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  Marina Konopleva; Peter F Thall; Cecilia Arana Yi; Gautam Borthakur; Andrew Coveler; Carlos Bueso-Ramos; Juliana Benito; Sergej Konoplev; Yongchuan Gu; Farhad Ravandi; Elias Jabbour; Stefan Faderl; Deborah Thomas; Jorge Cortes; Tapan Kadia; Steven Kornblau; Naval Daver; Naveen Pemmaraju; Hoang Q Nguyen; Jennie Feliu; Hongbo Lu; Caimiao Wei; William R Wilson; Teresa J Melink; John C Gutheil; Michael Andreeff; Elihu H Estey; Hagop Kantarjian
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 3.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

4.  Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of Acute myeloid leukemia.

Authors:  Masoumeh Kiani-Zadeh; Mohammad Reza Rezvany; Soodeh Namjoo; Mahmood Barati; Mohammad Hossein Mohammadi; Bahare Ghasemi; Tahere Tabatabaei; Ardeshir Ghavamzadeh; Farhad Zaker; Ladan Teimoori-Toolabi
Journal:  Mol Biol Rep       Date:  2022-06-22       Impact factor: 2.742

Review 5.  Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia.

Authors:  Fuling Zhou; Qiang Shen; François X Claret
Journal:  J Leukoc Biol       Date:  2013-05-28       Impact factor: 4.962

6.  HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia.

Authors:  Amina M Abdul-Aziz; Manar S Shafat; Yu Sun; Christopher R Marlein; Rachel E Piddock; Stephen D Robinson; Dylan R Edwards; Zhigang Zhou; Angela Collins; Kristian M Bowles; Stuart A Rushworth
Journal:  Oncogene       Date:  2018-02-28       Impact factor: 9.867

7.  High concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1α transcription.

Authors:  Hiroshi Kawada; Mitsuyo Kaneko; Masakazu Sawanobori; Tomoko Uno; Hideyuki Matsuzawa; Yoshihiko Nakamura; Hiromichi Matsushita; Kiyoshi Ando
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 8.  Drugging the unfolded protein response in acute leukemias.

Authors:  Behzad Kharabi Masouleh; Eric Chevet; Jens Panse; Edgar Jost; Michael O'Dwyer; Tim H Bruemmendorf; Afshin Samali
Journal:  J Hematol Oncol       Date:  2015-07-16       Impact factor: 17.388

9.  Hypoxia inducible factor 1α expression and effects of its inhibitors in canine lymphoma.

Authors:  Satoshi Kambayashi; Masaya Igase; Kosuke Kobayashi; Ayana Kimura; Takako Shimokawa Miyama; Kenji Baba; Shunsuke Noguchi; Takuya Mizuno; Masaru Okuda
Journal:  J Vet Med Sci       Date:  2015-06-06       Impact factor: 1.267

Review 10.  The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.

Authors:  Samantha Bruno; Manuela Mancini; Sara De Santis; Cecilia Monaldi; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.